published meta-analysis   sensitivity analysis   studies

anti-inflammatoty and immuno-therapy in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsRashad, 2021 2.86 [1.36; 6.01] Rashad, 2021 0.35 [0.17; 0.74] 1.00[0.13; 7.83]Rashad, 2021, Rashad, 2021293%298seriousnot evaluable deathsdetailed resultsRashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 0.46 [0.24; 0.88] 1.00[0.22; 4.55]Rashad, 2021, Rashad, 2021291%298seriousnot evaluable deaths (time to event analysis only)detailed resultsRashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 0.46 [0.24; 0.88] 1.00[0.22; 4.55]Rashad, 2021, Rashad, 2021291%298seriousnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-17 20:28 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525 - roots T: 290